The integrase inhibitor raltegravir (RAL) is currently used for the treatment of both treatmentnaïve and treatment-experienced HIV-1 infected patients. Elvitegravir (EVG) is in late phases of clinical development. Since a significant cross resistance is observed between RAL and EVG, there is need for second generation integrase inhibitors (INIs) with a higher genetic barrier and 
INTRODUCTION
Integration of viral DNA is an essential step in the HIV life cycle and is catalyzed by the viral integrase (IN) enzyme. This protein is encoded by the 3' end of the HIV-1 pol gene, containing 288 amino acids and functions as a tetramer (11) . The integration process consists of multiple steps (3, 6, 7) . First, a stable complex is formed between the IN enzyme and specific viral sequences at the end of the long terminal repeats (LTRs). The 3' processing step consists of the cleavage of the GT dinucleotide from each 3' end of the viral DNA. Subsequently, this preintegration complex migrates towards the nucleus where the strand transfer takes place, i.e. the stable insertion of the viral DNA into the host genomic DNA. Finally, the DNA gaps are repaired by host enzymes. Each of these steps can potentially be considered as a drug target.
Although many compounds have been reported to inhibit IN activity, to date, only the strand transfer inhibitors have been proven to be effective in vivo. While raltegravir (RAL; MK-0518) is currently approved by the FDA for use in both treatment-naïve and treatment-experienced patients, elvitegravir (EVG; GS-9137) is in late stages of clinical development (1, 10) .
Resistance to RAL occurs through three main pathways: Q148H/K/R, N155H and less frequently Y143R/C (3, 5) . Additional secondary mutations in IN that either further decrease the susceptibility or increase the fitness of the virus have been reported. In patients failing EVG treatment, the mutations T66I, E92Q, S147G, Q148H/K/R and N155H were identified (3), suggesting a significant cross resistance between RAL and EVG. There is need for second generation IN inhibitors (INIs) with a higher genetic barrier and limited cross resistance to RAL/EVG. Several potential second generation INIs are in preclinical development, including MK-2048 (19) , Compound G (19) and S/GSK1349572 (16, 17) .
MATERIALS & METHODS

Samples
Experiments were performed on a panel of 139 plasma samples, derived from 106 HIV-1 patients. For some patients, serum samples were collected on different points in time during RAL treatment. Informed consent was available.
Site-directed mutant plasmids (SDMs)
Site-directed mutants in the IN coding region, known to be associated with INI resistance, were constructed in the pUC19-5'HXB2D plasmid by using the Quickchange site-directed mutagenesis kit (Stratagene) (pUC19 containing the HIV genome from 5'LTR to the start of Env) (9, 20) . In total, 11 SDMs were generated: Q148H/G140S, Q148R, N155H, E92Q, S147G, T66I, T66A, V72I/E92Q/E157Q, E92Q/S147G, Y143R and E92Q/N155H.
IN amplification and purification
Viral RNA was isolated, either starting from 256 µl plasma using the automated QIAamp Virus BioRobot MDx extraction platform (Qiagen) or from 600 µl plasma using the EasyMAG procedure (BioMérieux) according to the manufacturer's instructions. cDNA was generated using the Accuscript High Fidelity Reverse Transcriptase (Stratagene) with random hexamers (Invitrogen). Subsequently, the IN gene was amplified by nested PCR using forward primers (19) and Compound G (19) ) were chemically synthesized in-house. Biological cutoff values for RAL and EVG were used as defined in (20) 
Statistics
Fold chance values were log transformed and genotypically assigned to either one of six primary mutation groups (i.e. Q148R, Q148H, N155H, Y143C, Y143R, Q148K). FC values derived from non primary mutation genotypes were used as a reference (i.e. no primary mutation (NPM)). 
RESULTS & DISCUSSION
Cross resistance between 4 INIs was studied in two populations of recombinant viruses, one derived from a selection of SDMs and one derived from clinical isolates.
First, susceptibility testing to RAL and EVG was performed on 11 SDMs (9, 20), known to be associated with resistance to INIs. Results were in concordance with previous data (20) and confirmed the high degree of cross resistance between RAL and EVG using SDMs ( Table 1 ).
The 11 SDMs were also tested for their susceptibility to two second generation INIs, MK-2048 and Compound G ( Table 1) . FC values ranged from 0.2 (T66I) to 12.6 (Q148H/G140S) for MK-2048 and from 0.3 (T66I) to 5.3 (N155H) for Compound G. Two double mutants (Q148H/G140S and E92Q/N155H) had reduced susceptibility for MK-2048. Only the N155H mutation resulted in a slightly elevated fold change value for Compound G.
Secondly, a total of 139 RVSs derived from patient's plasma samples, were available for susceptibility testing for the different INIs. Thirty six samples contained a primary mutation known to cause resistance to RAL. Secondary mutations at residue 140 were found in all isolates with the Q148H/K/R pathway; three samples also had the E138K/A mutation. In the Y143R/C pathway additional mutations like T97A, E138D and Q95K were found. The mutations E92Q/A, Q95K, and E138D were also found in the N155H pathway (Table 2 ). These co-existence of mutations with the primary mutation pathways are in concordance with previously reported studies (2, 4, 5, 8, (13) (14) (15) 18) .
The 139 RVSs derived from clinical isolates were tested for their susceptibility to RAL and EVG. The median of the RAL and EVG FC values was calculated ( Table 2) . The proc mixed model showed that the two main factors (i.e. genotype, compound) contributed significantly to the observed variation in log FC. In addition the two-way interaction was also highly significant, on July 9, 2017 by guest http://aac.asm.org/ Downloaded from indicating that differences in log FC among the four compounds varied depending on the genotype taken under consideration (Table 3 ). This significant interaction was largely determined by the fact that the highest FC values were found in EVG for all genotype groups, except for Y143R and Y143C where they dropped below the RAL FC values (Tables 2, 3; Fig   2) . Viruses with Q148H/K/R mutations had a highly reduced susceptibility for both RAL and EVG, while samples with mutations in the N155H pathway were only slightly reduced for both these compounds ( (Table 2 ).
In addition, 75 out of the 139 RVSs derived from clinical isolates were tested for their susceptibility to MK-2048 and compound G ( Table 2, Fig 2) . Compound G resulted in the lowest FC values, irrespective from the genotype which is taken under consideration ( Table 2, Fig 2) . Samples with the Q148R or Q148H mutation had reduced susceptibility to both MK-2048 and compound G ( Table 2, Fig 2) . A large difference in FC value between the SDM with the Q148R mutation and the clinical isolates containing the Q148R mutation could be found for all compounds tested (for MK-2048: FC value of 2 for SDM Q148R versus mean FC value of 245 for the clinical isolates). This could be explained by the presence of the secondary mutation on position 140 (G140S or G140A) in all clinical isolates containing the Q148R mutation (Table 2) .
Although samples with the Y143R/C mutation had a reduced susceptibility for RAL, they on July 9, 2017 by guest http://aac.asm.org/ Downloaded from remained susceptible to two investigated second generation INIs (Fig 2 p>0.05) . The presence of the secondary mutation T97A did not reduce the susceptibility for the two compounds (Table 2) .
However, one sample containing the Y143R, T97A, E138D, L74M and G163N mutations had a slightly reduced susceptibility for MK-2048 (FC value of 4.5). Samples with the N155H mutation had no reduced susceptibility for Compound G (median FC value of 1.2; Fig 2) . A few samples with the N155H mutation had, however, slightly increased FC values for MK-2048, due to the presence of secondary mutations. For example, one sample containing both the N155H and Q95K mutation had a FC value of 13.7 for MK-2048 (Table 2) . ---S  -H  ---450  940  ND  ND   17  -----S  -H  ---483  940  ND  ND   18  -----S  -H  ---908  940  283  4.6   19  -----S  -H  ---515  504  169  3.3   20  -----S  -H  ---597  837  62.0  2.6   21  -----S  -H  ---337  793  ND  ND   22  -----S  -H  ---648  893  ND  ND   23  -----S  -H  ---215  793  ND  ND   24  ----K,E  S  -H  ---273  893  ND  ND   25  ----E,A  S  -H  ---650  837 
